Pumpkin spice overnight oats are nourishing - any time of day - The Globe and Mail
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Open this photo in gallery:Julie Van Rosendaal/The Globe and MailWhen artist, zinester and writer Sonali Menezes found herself struggling with mental illness, disordered eating and, as she puts it, the crushing weight of capitalism, she practised self-care by feeding herself well. In 2022, her efforts turned into a zine (a self-published, hand-produced mini-magazine) called Depression Cooking. From her home in Hamilton, Menezes printed hundreds of copies at a time, enlisting friends and family to help collate, fold, staple, package and mail them around the world. Now a full-fledged book, Depression Cooking: Feeding Yourself When It All Feels Too Hard contains 25 chapters of stories, life lessons and recipes, with endearing titles (Cooking as an Excuse to Listen to Music and If the Anti-Diet God Exists, She Will Test You), each focused on a challenging time in her life, when food seemed more enemy than ally. “Depression Cooking is intended to be a tool to support and comfort,” she writes.
This article is an excerpt. To read the full content, visit the original source. The Globe and Mail
Related articles
World Pulses Day 2024 | Pulses: nourishing soils and people - Food and Agriculture Organization
Survodutide for Type 2 Diabetes and Obesity | Metabolic Care Today - DocWireNews
Type 2 DiabetesSurvodutide Reduced Body Weight for Patients With Type 2 Diabetes and ObesityType 2 DiabetesSurvodutide Reduced Body Weight for Patients With Type 2 Diabetes and ObesityPublished: October 21, 2026The SYNCHRONIZE-2 trial is a multinational, double-blind phase 3 trial conducted by Sean Wharton, MD, PharmD, of McMaster University in Hamilton, Ontario, Canada, and colleagues to evaluate the investigational glucagon receptor–glucagon-like peptide-1 receptor dual agonist survodutide. For patients with both type 2 diabetes and obesity, Dr. Wharton and colleagues wrote, “Weight management may be the most effective therapy for type 2 diabetes.”This trial enrolled 752 patients with type 2 diabetes and a BMI of at least 27. Patients were randomly assigned on a 1-to-1-to-1 basis to receive 3.6 mg of survodutide (n=250), 6.0 mg of survodutide (n=251), or placebo (n = 251) by once-weekly injection. The primary end points were percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76. The mean weight change at week 76 (treatment-regimen estimand) was –8.2% in the 3.6-mg group, –9.8% in the 6.0-mg group, and –3.9% in the placebo group.
Sask. outbreak raises concerns prompting prevention reminders - CTV News
AtlanticNova ScotiaNew BrunswickPrince Edward Island Newfoundland and LabradorCalgaryLethbridgeKitchenerGuelphNorthern OntarioSudburyNorth BaySault Ste. MarieTimminsOttawaKingstonBrockvillePembrokeReginaYorktonSaskatoonPrince AlbertTorontoWatchWeatherPeelHamiltonDurhamYorkHaltonNiagaraQueen's ParkToronto City HallIn PicturesVancouverVancouver IslandCanadaLocal SpotlightRoyal FamilyPoliticsNanosPower PlayQuestion PeriodFederal Election 2025WorldMideast ConflictRussia-Ukraine WarWatchLatestCaptured on CameraPoliticsLifestyleConsumerHealthExplainedEntertainmentTechnologyDeception DecodedAutosEnvironmentBusinessInflationReal EstateAutos
0 comments
No comments yet. Be the first to share your thoughts!